Regenerative Medical Technology Group Reports 24.17% Revenue Growth but Increases Net Loss to $7.8 Million

Regenerative Medical Technology Group Inc. (RMTG) reported a revenue increase of 24.17% for the fiscal year ending December 31, 2025, totaling $5.1 million compared to $4.1 million in 2024. Despite this growth, the company experienced a net loss of $7.8 million, a significant increase from the previous year's loss of $5.6 million. The rise in revenue was attributed to expanded product distribution networks and increased patient volumes, particularly in stem cell-related products. However, the cost of revenue also surged by 78.26%, leading to a slight decline in gross profit margin.

Operating expenses rose by 34.14%, driven by increased advertising and marketing costs, professional fees, and general administrative expenses. The company invested heavily in marketing efforts to enhance brand recognition and attract new affiliates through its International Society for Stem Cell Applications (ISSCA) programs. This strategic focus on education and training is expected to yield long-term benefits, although it has contributed to the current financial strain. The company also reported a significant increase in interest expenses, totaling $7.4 million, which further exacerbated its financial challenges.

RMTG's operational developments included the expansion of its manufacturing capabilities through its subsidiary, Global Stem Cells Group, and the establishment of a comprehensive clinical network. The company has made strides in geographic expansion, particularly in Latin America, where it has aligned its operations with local regulatory frameworks to enhance product distribution. The ISSCA's educational initiatives have solidified RMTG's position as a leader in regenerative medicine education, facilitating the adoption of its protocols and products among physicians.

Looking ahead, RMTG anticipates continued revenue growth driven by its vertically integrated model and strategic initiatives aimed at enhancing operational efficiencies. The company plans to focus on expanding its clinical network and product offerings while navigating the challenges posed by its current financial condition. Management has expressed the need for additional financing to support ongoing operations and growth initiatives, emphasizing the importance of securing capital to ensure the company's sustainability. The outlook remains cautious, with substantial doubt raised about the company's ability to continue as a going concern without successful capital raising efforts.